<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04760314</url>
  </required_header>
  <id_info>
    <org_study_id>17953</org_study_id>
    <secondary_id>J2T-JE-KGAL</secondary_id>
    <nct_id>NCT04760314</nct_id>
  </id_info>
  <brief_title>A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis</brief_title>
  <acronym>ADhere-J</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination With Topical Corticosteroid Treatment in Japanese Patients With Moderate-to-Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in&#xD;
      combination with a topical corticosteroids in Japanese participants with atopic dermatitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 10, 2021</start_date>
  <completion_date type="Anticipated">January 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with an Investigators Global Assessment (IGA) score of 0 or 1 and a reduction ≥2 points from Baseline to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Percentage of participants with an IGA score of 0 or 1 and a reduction ≥2 points from Baseline to Week 16</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants achieving Eczema Area Severity Index-75 (EASI-75) (≥75% reduction in EASI score) from Baseline to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Percentage of participants achieving EASI-75 (≥75% reduction in EASI score) from Baseline to Week 16</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Eczema Area Severity Index (EASI) score from Baseline</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Percent change in EASI score from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants achieving EASI-90</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Percentage of Participants achieving EASI-90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with an Itch Numeric Rating Scale (NRS) Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction from Baseline</measure>
    <time_frame>Baseline to Week 1</time_frame>
    <description>Percentage of Participants with an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction from Baseline</measure>
    <time_frame>Baseline to Week 2</time_frame>
    <description>Percentage of Participants with an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction from Baseline</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Percentage of Participants with an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction from Baseline</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Percentage of Participants with an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction from Baseline</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <condition>Dermatitis</condition>
  <condition>Eczema</condition>
  <condition>Skin Diseases</condition>
  <condition>Skin Diseases, Genetic</condition>
  <arm_group>
    <arm_group_label>Lebrikizumab Regimen A + Topical Corticosteroid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lebrikizumab Regimen A administered by subcutaneous (SC) injection in combination with topical corticosteroid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lebrikizumab Regimen B + Topical Corticosteroid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lebrikizumab Regimen B administered by SC injection in combination with topical corticosteroid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Topical Corticosteroid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered by SC injection in combination with topical corticosteroid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lebrikizumab</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Lebrikizumab Regimen A + Topical Corticosteroid</arm_group_label>
    <arm_group_label>Lebrikizumab Regimen B + Topical Corticosteroid</arm_group_label>
    <other_name>LY3650150</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo + Topical Corticosteroid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Corticosteroid</intervention_name>
    <description>Self-applied</description>
    <arm_group_label>Lebrikizumab Regimen A + Topical Corticosteroid</arm_group_label>
    <arm_group_label>Lebrikizumab Regimen B + Topical Corticosteroid</arm_group_label>
    <arm_group_label>Placebo + Topical Corticosteroid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have chronic Atopic Dermatitis (AD) that has been present for ≥1 year before the&#xD;
             screening.&#xD;
&#xD;
          -  Have moderate-to-severe AD, including all of the following:&#xD;
&#xD;
               -  EASI score ≥16 at the baseline&#xD;
&#xD;
               -  IGA score ≥3 (scale of 0 to 4) at the baseline&#xD;
&#xD;
               -  AD involvement on ≥10% of Body Surface Area (BSA) at the baseline&#xD;
&#xD;
          -  Have a documented history provided by a physician and/or investigator of inadequate&#xD;
             response to existing topical medications within 6 months preceding screening as&#xD;
             defined by at least 1 of the following:&#xD;
&#xD;
               -  Inability to achieve good disease control, defined as mild disease or better (for&#xD;
                  example, IGA ≤2) after use of at least a medium-potency topical corticosteroids&#xD;
                  (TCS) for at least 4 weeks, or for the maximum duration recommended by the&#xD;
                  product prescribing information (for example, 14 days for super-potent TCS),&#xD;
                  whichever is shorter. Topical corticosteroids may be used with or without Topical&#xD;
                  calcineurin inhibitors (TCI) and/or topical Janus Kinase (JAK) inhibitors.&#xD;
&#xD;
               -  Participants who failed systemic therapies intended to treat AD within 6 months&#xD;
                  preceding screening, such as cyclosporine, methotrexate (MTX), azathioprine, and&#xD;
                  mycophenolate mofetil (MMF), will also be considered as surrogates for having&#xD;
                  inadequate response to topical therapy.&#xD;
&#xD;
          -  Body weight ≥40 kilogram (kg)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a history of anaphylaxis&#xD;
&#xD;
          -  Have uncontrolled chronic disease that might require bursts of oral corticosteroids&#xD;
             for example, comorbid severe uncontrolled asthma within the past 12 months requiring&#xD;
             systemic corticosteroid treatment or hospitalization for &gt;24 hours at baseline.&#xD;
&#xD;
          -  Have an active chronic or acute infection requiring treatment with systemic&#xD;
             antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks&#xD;
             before the baseline or superficial skin infections within 1 week before the baseline.&#xD;
&#xD;
          -  Evidence of acute or chronic hepatitis or known liver cirrhosis.&#xD;
&#xD;
          -  Have a history of pneumocystis pneumonia (PCP) or a positive beta-D-glucan test at&#xD;
             screening and a confirmed diagnosis of PCP.&#xD;
&#xD;
          -  Have a history of human immunodeficiency virus (HIV) infection or positive HIV&#xD;
             serology at screening.&#xD;
&#xD;
          -  Have presence of skin comorbidities (for example, sclerosis, psoriasis, or lupus&#xD;
             erythematosus) that may interfere with study assessments.&#xD;
&#xD;
          -  Have presence of significant uncontrolled neuropsychiatric disorder.&#xD;
&#xD;
          -  Have been exposed to a live vaccine within 12 weeks prior to baseline or are expected&#xD;
             to need/receive a live vaccine during the study or up to 125 days after the last dose&#xD;
             of study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yanagihara dermatology clinic</name>
      <address>
        <city>Ainokawa, Ichikawa-shi</city>
        <state>Chiba</state>
        <zip>272-0143</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kawashima Dermatology Clinic</name>
      <address>
        <city>Ichikawa-shi</city>
        <state>Chiba</state>
        <zip>272-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charme Clinique</name>
      <address>
        <city>Matsudo</city>
        <state>Chiba</state>
        <zip>270-2223</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yasumoto Dermatology Clinic</name>
      <address>
        <city>Chikushino-city</city>
        <state>Fukuoka</state>
        <zip>818-0083</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hino Dermatology Clinic</name>
      <address>
        <city>Fukutsu</city>
        <state>Fukuoka</state>
        <zip>811-3217</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima-ken</state>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takagi Dermatology</name>
      <address>
        <city>Obihiro</city>
        <state>Hokkaido</state>
        <zip>080-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobayashi Skin Clinic</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>060-0807</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo Skin Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Shimizu Clinic</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>657-0846</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ibaraki Medical Center</name>
      <address>
        <city>Inashiki-gun</city>
        <state>Ibaraki</state>
        <zip>300-0395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KAJI Dermatology Clinic</name>
      <address>
        <city>Nonoichi-shi</city>
        <state>Ishikawa</state>
        <zip>921-8801</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosugi Dermatology Clinic</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>211-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Square Dermatology and Allergology</name>
      <address>
        <city>Nishi-ku, Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>220-6208</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nomura Dermatology Clinic</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>221-0825</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Noguchi Dermatology</name>
      <address>
        <city>Kashima-machi, Kamimashiki-gun</city>
        <state>Kumamoto</state>
        <zip>861-3101</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jyouzanhihuka・Hinyoukika Clinic</name>
      <address>
        <city>Kumamoto Shi</city>
        <state>Kumamoto</state>
        <zip>860-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Habikino Medical Center</name>
      <address>
        <city>Habikino</city>
        <state>Osaka</state>
        <zip>583-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mochida Dermatology Clinic</name>
      <address>
        <city>Izumiotsu-shi</city>
        <state>Osaka</state>
        <zip>595-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kume Clinic</name>
      <address>
        <city>Sakai City</city>
        <state>Osaka</state>
        <zip>593-8324</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yoshikawa Dermatology Clinic</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>569-0824</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanrui Dermatology Clinic</name>
      <address>
        <city>Ohmiya-ku,Saitama-shi</city>
        <state>Saitama</state>
        <zip>330-0854</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokkyo Medical University Hospital</name>
      <address>
        <city>Shimotsuga-Gun</city>
        <state>Tochigi</state>
        <zip>321 0293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akihabara Skin Clinic</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>101-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sumire Dermatology Clinic</name>
      <address>
        <city>Edogawa-ku</city>
        <state>Tokyo</state>
        <zip>133-0057</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maruyama Dermatology Clinic</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>136-0074</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamaguchi Skin Clinic</name>
      <address>
        <city>Machida-shi</city>
        <state>Tokyo</state>
        <zip>194-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mita Dermatology Clinic</name>
      <address>
        <city>Minato-Ku</city>
        <state>Tokyo</state>
        <zip>108-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanpopo Dermatology Clinic</name>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <zip>143-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamate Dermatological Clinic</name>
      <address>
        <city>Shinjuku</city>
        <state>Tokyo</state>
        <zip>169-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yoshihara Dermatology Clinic</name>
      <address>
        <city>Sumida-ku</city>
        <state>Tokyo</state>
        <zip>130-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tachikawa Dermatology Clinic</name>
      <address>
        <city>Tachikawa-shi</city>
        <state>Tokyo</state>
        <zip>190-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shirasaki Clinic</name>
      <address>
        <city>Takaoka-shi</city>
        <state>Toyama</state>
        <zip>9330871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsuda Tomoko Dermatological Clinic</name>
      <address>
        <city>Fukuoka</city>
        <zip>819-0167</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto Furitsu Medical University Hospital</name>
      <address>
        <city>Kyoto-shi</city>
        <zip>602 8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goto Dermatology Clinic</name>
      <address>
        <city>Osaka</city>
        <zip>554-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/6Snw910hnAdavPQabysPCL</url>
    <description>A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis (ADhere-J)</description>
  </link>
  <verification_date>September 1, 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Skin Diseases, Genetic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

